A phase 3 trial evaluating apremilast in children and adolescents with moderate-to-severe plaque psoriasis showed improvements in disease severity compared with placebo over 16 weeks.
A recent phase 3b long-term extension study assessed the safety and efficacy of deucravacitinib over 2 years in patients with moderate-to-severe plaque psoriasis.
Despite being approved for use, consensus among the real-world data on the use of IL-23 inhibitors in psoriatic disease has been lacking; therefore, researchers recently examined the drug survival and...
In a post hoc analysis of the EXCEED study, researchers found that secukinumab and adalimumab—two biologic disease-modifying antirheumatic medications—showed similar efficacy in the resolution of enthesitis...
The authors of a recent study aimed to determine if the use of routine ultrasound could be an effective tool for screening patients with psoriasis for subclinical psoriatic arthritis.
Previous research has linked suicidal risk with psoriasis and atopic dermatitis. In order to examine this relationship further, researchers conducted a review of reports of suicidal ideation, attempts, and...
In a recent study, researchers examined the relationship between exercise, cardiorespiratory fitness, pulse wave velocity, and risk of future cardiovascular disease in patients with psoriasis.
